BioStem Technologies (OTCMKTS:BSEM) said its first quarter of 2026 marked a major shift in its business model following a late-January acquisition that moved the company’s focus from physician offices toward the hospital market.
Chairman and Chief Executive Officer Jason Matuszewski called the quarter “a transformational period,” saying the acquisition added a portfolio of perinatal tissue allografts, an experienced sales organization, hospital customers and major group purchasing organization contracts. He said the transaction expanded BioStem’s addressable market and increased its exposure to commercially insured patient populations.
